SecBot SecBot
PRESS-RELEASE ·Filed Jun 18, 2026

DNLI

Denali Therapeutics Inc.
BULLISH
Impact 6/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

The $195M PRV sale provides a meaningful cash runway extension without dilution. Monitor for pipeline catalysts (DNL126, DNL593, DNL952) and any updates on the HSR clearance timeline. The cash strengthens Denali's ability to advance its clinical programs, but execution risk remains.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$23.31
T+0 close · Jun 18, 2026 · via day close
Latest settled
−8.97%
T+60 · $21.22
Vs SPY
−10.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 18 $23.31entry
  2. T+1 · 5mo ago +3.17%α +3.49% · $24.05
  3. T+5 · 5mo ago +6.09%α +7.76% · $24.73
  4. T+20 · 4mo ago −2.49%α −3.02% · $22.73
  5. T+60 · 2mo ago −8.97%α −10.86% · $21.22
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in gross proceeds. The PRV was awarded following FDA approval of AVLAYAH for Hunter syndrome in March 2026. The non-dilutive cash infusion strengthens Denali's financial flexibility and will fund its clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.

Key Financial Metrics

Deal Value
$195.0M

Key Facts

  • Denali entered a definitive agreement to sell its Rare Pediatric Disease PRV for $195 million gross proceeds.
  • The PRV was awarded after FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.
  • Proceeds will support Denali's TransportVehicle-enabled clinical pipeline, including DNL126, DNL593, DNL952, and DNL628.
  • The transaction is subject to customary closing conditions, including HSR Act waiting period expiration.

Financial Impact

$195 million non-dilutive cash infusion, representing ~5.3% of Denali's $3.7B market cap.

cashcash runway

Risk Factors

  • PRV sale is subject to HSR waiting period and customary closing conditions.
  • Pipeline programs are still in clinical/IND-enabling stages with no guarantee of success.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3314101

Track record

17 reports on DNLI

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +23.19% at T+60 after the May 7, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $18.75 Now $18.08 −3.55% settles Nov 17
  2. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  3. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $20.96 to $19.72 Now $18.08 −13.74% ▼ −5.92% −1.51% vs SPY
  4. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $18.94 to $18.86 Now $18.08 −4.54% ▼ −0.42% +0.06% vs SPY
  5. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $18.66 Now $18.08 −3.11% No price data
  6. Sep 9, 20269w ago Insider Cluster Neutral 2/10 Entry $21.40 to $21.09 Now $18.08 −15.51% ▼ −1.45% −2.30% vs SPY
  7. Sep 4, 202610w ago Insider Cluster Neutral 2/10 Entry $22.08 to $21.57 Now $18.08 −18.12% ▼ −2.31% −1.84% vs SPY
  8. Aug 6, 202614w ago 8-K Mixed 6/10 Entry $24.83 to $25.00 Now $18.08 −27.18% ▲ +0.68% +0.71% vs SPY
  9. Jul 27, 202616w ago Press Release Neutral 1/10 Entry $24.05 Now $18.08 −24.82% No price data
  10. Jun 18, 202621w ago 8-K Bullish 6/10 Entry $23.31 to $24.05 Now $18.08 −22.44% ▲ +3.17% +3.49% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens Wed (10h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026